Response to paclitaxel in adenoid cystic carcinoma of the salivary glands
β Scribed by Brian G. Till; Renato G. Martins
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 140 KB
- Volume
- 30
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Background.
Paclitaxel is not considered to be an active drug in adenoid cystic carcinoma (ACC) of the salivary glands. We report 2 consecutive cases of patients with ACC who responded to paclitaxel.
Methods.
The patients were: (1) a 58βyearβold man with recurrent ACC who developed pulmonary metastases, had progressive disease after a good response to firstβline chemotherapy, and then achieved a partial response to weekly singleβ agent paclitaxel; and (2) a 46βyearβold woman with extensive thoracic ACC metastases who achieved a significant response after 2 cycles of paclitaxel chemotherapy.
Results.
The first patient died of progressive disease approximately 4 months after completing paclitaxel therapy, and the second patient had disease control after 6 cycles of paclitaxel.
Conclusions.
Systemic weekly paclitaxel produced a significant response in 2 patients with ACC of the head and neck, and its use in this disease merits further study. Β© 2007 Wiley Periodicals, Inc. Head Neck, 2008
π SIMILAR VOLUMES
The cytomorphologic features in fine-needle aspiration (FNA) biopsies from 31 primary and 33 recurrent adenoid cystic carcinomas (ACC) were investigated. The correct FNA diagnosis was established in 24 of 31 primary ACC (77%). The diagnostic clue in aspirates from ACC are large globules of extracell
## Background: Epidermal growth factor (egf) and its receptor (egfr) are involved in the development of salivary gland tumors. recently, treatment modalities for egfr inhibition have shown an enhanced clinical response in carcinomas of different locations. adenoid cystic carcinoma (acc) of salivary
The objective of this study was to clarify extracellular materials (ECMs) in adenoid cystic carcinoma (AdCC) and compare these to those found in other salivary gland tumors with myoepithelial differentiation. The ECM was examined with Papanicolaou, May-GrΓΌnwald-Giemsa (MGG), and alcian blue stain at
A 55-year-old man had adenoid cystic carcinoma of the esophagus metastatic to the lungs and right supraclavicular fossa. He was treated with local radiation therapy to the esophagus and supraclavicular fossa, followed by combination chemotherapy with doxorubicin, mitomycin C, and 5-fluorouracil(5-FU